ArticleJournal of cosmetic dermatology2025
BOTME Study: A National e-Delphi Study on the Use of Botulinum Toxin for Aesthetic Treatment of Middle Easterners.
Article in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- BOTME Study: A National e-Delphi Study on the Use of Botulinum Toxin for Aesthetic Treatment of Middle Easterners.Journal of cosmetic dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe demand for botulinum toxin A (BTX-A) cosmetic treatments is growing among individuals with skin of color, primarily due to increased cultural acceptance, social media influence, and patient awareness. However, there remains a lack of standardized, evidence-based guidance on the use of BTX-A in these populations.
objectiveTo develop consensus-based clinical recommendations on aesthetic botulinum toxin injection practices in patients with skin of color.
methodsA modified e-Delphi method was conducted with 10 board-certified dermatologists specializing in cosmetic dermatology. Inclusion criteria required ≥ 5 years of experience and publications, or teaching activity in BTX-A use. Two e-Delphi rounds evaluated 29 evidence-based statements. Consensus was defined as ≥ 70% agreement.
resultsConsensus was achieved on 22 statements. Key recommendations included initiating BTX-A treatments at ages 30-35, dosing 40-60 IU for the upper face, with 16-20 week intervals, using 2 mL of saline reconstitution per 100 IU, and employing 30-gauge insulin syringes. Topical EMLA was collectively agreed upon for pain control. While several technical aspects, such as injection depth and under-eye applications, remained inconclusive, participants decided on key practical precautions, including posttreatment activity restrictions.
conclusionThese consensus-based recommendations can standardize, make BTX-A injections safe and effective for skin of color patients, supporting more uniform and comparable treatment results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.